- Coordinator
- Consiglio Nazionale Delle Ricerche, Italy
- Runs
- 1 September 2025 to 28 February 2027
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101212914
What the project is doing
In the project's own words, from its summary on CORDIS.
Accurately assessing hypoxia and acidosis in the tumor microenvironment is crucial for understanding tumor behavior and determining treatments effectiveness. These conditions, caused by uncontrolled cancer cell proliferation, are key indicators of aggressiveness and metastasis risk, yet remain difficult to measure precisely. The HySENSE project addresses this gap with an innovative sensor kit capable of real-time, cell-specific measurements of oxygen and pH at high spatio-temporal resolution.
This advanced technology surpasses current tools, offering deeper insights into tumor behavior and therapeutic effects. HySENSE will be validated using patient-derived colorectal cancer models, and a business feasibility study will define the path to commercialization. By enabling precise analysis of hypoxia and acidosis, HySENSE aims to transform cancer diagnostics and treatment planning, ultimately improving patient care.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Consiglio Nazionale Delle Ricerche | Roma | Italy | Coordinator |
| Day One Societa a Responsabilita Limitata | Roma Rm | Italy | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI